Edgar Filing: Clovis Oncology, Inc. - Form 4

Clovis Oncology, Form 4	Inc.									
June 16, 2014										
FORM 4						CTT A NOT			PPROVAL	
	UNITED	STATES					COMMISSIO	N OMB Number:	3235-0287	
Check this box if no longer subject to Section 16.	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								January 31, 2005 average	
Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Section 16. Filed pursuant to Section 16(a) of the Securities Exchange A Section 17(a) of the Public Utility Holding Company Act of 1940 30(h) of the Investment Company Act of 1940					of 1935 or Secti					
(Print or Type Respon	nses)									
1. Name and Address SPICKSCHEN T		Person [*]	Symbol	er Name and Oncology		-	5. Relationship Issuer	of Reporting Pe	rson(s) to	
(Last) (First) (I	Middle)		of Earliest T	_		(Che	eck all applicabl	le)	
C/O CLOVIS ON INC., 2525 28TH 100	NCOLOGY	,		Day/Year)	ransaction		X Director Officer (giv below)		% Owner her (specify	
				Filed(Month/Day/Year) Applic _X_Fo			Applicable Line) _X_ Form filed by Form filed by	K_ Form filed by One Reporting Person _ Form filed by More than One Reporting		
(City) (State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	ally Owned	
	insaction Date th/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report on	a separate line	e for each cla	ass of sec	urities benef	•	•	or indirectly. spond to the colle	ction of	SEC 1474	
					inforn requir	nation cont red to respo ays a curre	tained in this forn ond unless the fo ntly valid OMB co	n are not rm	(9-02)	
	Tab				-	posed of, or convertible	Beneficially Owner securities)	d		
1. Title of 2.	3. Trans	action Date	3A. Dee	emed	4.	5. Number	of 6. Date Exerci	sable and	7. Title and Amou	

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D

Edgar Filing: Clovis Oncology, Inc. - Form 4

Security (Instr. 3)	5		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)		5
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 44.52	06/12/2014		А	12,414		<u>(1)</u>	06/12/2024	Common Stock	12,414	

Reporting Owners

Reporting Owner Name / Address		Relationsh	ips	
	Director	10% Owner	Officer	Other
SPICKSCHEN THORLEF C/O CLOVIS ONCOLOGY, INC. 2525 28TH STREET, SUITE 100 BOULDER, CO 80301	Х			
Signatures				
/s/ Erle T. Mast, attorney-in-fact	06/16/20)14		
**Signature of Reporting Person	Date			

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) One-twelfth (1/12) of the shares subject to the option shall vest on each of the first twelve (12) monthly anniversaries of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (